NEW YORK (PRWEB) November 05, 2018
GlycoMark, Inc., the exclusive provider of the GlycoMark® test, is launching live educational support for healthcare professionals through its website, http://www.glycomark.com, as part of National Diabetes Month. The new complimentary educational support will offer a live chat and video option via the website in November from 9 a.m. – 5 p.m. ET weekdays for healthcare professionals to speak with GlycoMark experts. The website also includes access to expanded educational resources related to the GlycoMark Test for optimizing glycemic control in the more than 30 million Americans with diabetes.
“As a diagnostic company, we believe it is our responsibility to not only provide access to our test, but to also create awareness and educate clinicians on methods to improve glycemic control,” said Hiro Ishibashi, President of GlycoMark. “By implementing this web-based educational forum during National Diabetes Month, we hope to provide healthcare professionals with greater access to resources for the betterment and wellbeing of patients with diabetes.”
The GlycoMark Test, an FDA-cleared blood test that measures 1,5-anhydroglucitol (1,5-AG), is specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring while fasting, postprandial, or both). The GlycoMark test complements A1C, a 3-month glucose average and routine test for patients with diabetes, by revealing improving or worsening control for the prior one to two weeks for a more timely assessment of treatment response and compliance.
GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, Asia-Pacific region and the Middle East. The GlycoMark test is an FDA cleared, non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at http://www.GlycoMark.com.
The information contained in the live educational support is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.
The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to identify patients that will experience complications of diabetes or reduce the likelihood of experiencing complications.
GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo.